Biomedical subjects

R Gottschalk

Publications and source records attributed to R Gottschalk.

60 records · Page 4Linked to original sources

PubMed1979

[Characterization and comparison of the clinical and morphological changes in adriamycin cardiomyopathy].

Through comparative clinical and pathological findings a dose-response relationship for the cardiotoxic effect of adriamycine could be proved. A myocardial damage without clinical relation could already be seen at a dose of 125 mg/m2 body surface by patho-histological examination. Therefore, all patients being treated with adriamycine should be regularly and carefully cardiologically supervised in order to avoid an irreversible cardiomyopathy.

Adult↗

PubMed1978

[New methods in early diagnosis of a cardiomyopathy caused by adriamycin].

The cytostatic drug Adriamycin can, when given in overdose, cause a congestive (dilative) cardiomyopathy. In 120 patients, chest X-ray and ECG proved unsuitable for the early detection of this cardiomyopathy. However, a relatively early diagnosis of a cardiomyopathy can be made using echocardiography, radiocardiography, including determination of the minimal cardiac transit time, and through the determination of systolic time intervals. Especially the latter method represents a simple, economic, and yet exact means for the early recognition of Adriamycin-induced cardiomyopathy.

Cardiomegaly↗

PubMed1977

Use of heterogenous and monospecific antisera for the diagnosis of bladder cancer.

A rabbit antibody to antigens present in urine from bladder cancer patients was prepared and used in conjunction with various monospecific antisera to detect urine components related to bladder cancer. All urine samples were centrifuged routinely, dialyzed and concentrated 10 times before assay by gel diffusion versus the various antisera. Urine was considered positive when it showed reactivity with 2 or more antibodies. This method of analysis resulted in the diagnosis of 64% of the bladder papillomas and 77% of the bladder cancers tested, compared to only a 7% falsely positive rate with normal urine. These data support the potential usefulness of an antiserum panel in the immunological diagnosis of bladder cancer in the general population and in high risk individuals.

Animals↗

PubMedDate not supplied

[Detection of dsDNA antibodies in diagnosis of systemic lupus erythematosus--comparative studies of diagnostic effectiveness of 3 ELISA methods with different antigens and a Crithidia luciliae immunofluorescence test].

Antibodies to double-stranded DNA (anti-dsDNA, dsDNA-Ab) are frequently found in systemic lupus erythematosus (SLE), especially during active disease and differ with respect to immunoglobulin class and avidity. The detection of anti-dsDNA is one of the diagnostic criteria for SLE according to the American College of Rheumatology (ACR). Most of the commercial ELISA test systems have great advantages in routine laboratory testing but often detect dsDNA-Ab which are not specific for SLE and therefore give false positive results for non-SLE patients. The newly developed ELISA presented here, using human recombinant dsDNA (h-Rek) is compared to two commercial ELISA tests with genomic dsDNA from salmon testes (L-dsDNA) or plasmid dsDNA (P-dsDNA) and to the Chrithidia luciliae immunofluorescence test (CLIF) as well. In this study 143 sera were tested, 48 derived from patients with SLE, 40 from rheumatoid arthritis patients, 26 from non-rheumatoid patients whose sera were ANA-negative but L-dsDNA-Ab-positive and 30 from healthy volunteers. All patients were followed and clinically defined by the rheumatology outpatient clinic of our hospital. The prevalence for SLE of all sera was 32%. The sensitivity was 0.73 (h-Rek), 0.83 (L-dsDNA), 0.81 (P-dsDNA) and 0.57 (CLIF); specificity was determined 0.84 (h-Rek), 0.62 (L-dsDNA), 0.63 (P-dsDNA) and 0.98 (CLIF). The diagnostic efficiency of the L-dsDNA- and P-dsDNA-assay was identical, 0.69, and amounted to 0.81 for the h-Rek and 0.84 for the CLIF. Comparing all the ELISA tests and CLIF, the human recombinant dsDNA ELISA is much more sensitive than the CLIF, but considerably more specific than the ELISA assays using genomic or plasmid DNA, whereas the diagnostic efficiency is very close to that of the CLIF. This new generation of anti-dsDNA ELISA using human recombinant dsDNA seems to be a much better diagnostic tool for the detection of highly specific anti-dsDNA antibodies in the diagnosis of SLE than other commercial ELISAs. These results can only be explained by the use of a human recombinant antigen instead of undefined genomic or recombinant plasmid DNA for immobilization.

Animals↗

PubMedDate not supplied

[Hemochromatosis arthropathy--an early manifestation of genetic hemochromatosis].

Recent studies have shown a high frequency of genetic hemochromatosis in the Caucasian population. In addition, the well known organ involvement of genetic hemochromatosis was evident; more than 50% of patients develop a typical arthropathy which may result in severe physical disability. Among approximately 5000 patients referred to the rheumatology outpatient clinics of Bad Nauheim and Frankfurt with different rheumatologic diagnoses, 11 patients with typical signs of hemochromatotic arthropathy were identified. In none of those cases had the diagnosis "genetic hemochromatosis" been previously established. These patients had been treated for rheumatoid arthritis and other rheumatologic disorders over several years. All showed severe organ dysfunction due to iron overload, resulting in a reduced life expectancy. This investigation shows that knowledge of the typical signs of hemochromatotic arthropathy could lead to an earlier diagnosis of genetic hemochromatosis which is necessary to prevent the complications of iron overload in those patients.

Adult↗

PubMedDate not supplied

Microscopic acanthosis nigricans in type 2 diabetes.

BACKGROUND: Acanthosis nigricans (AN) has been associated with insulin resistance. Individuals with type 2 diabetes are insulin-resistant and, therefore, could be expected to manifest AN. However, the prevalence and predictors of AN are unknown in this population. OBJECTIVE: An outpatient population with Type 2 diabetes (DM) was compared with matched controls (C) for microscopic and clinical AN along with measurement of body habitus, insulin, glucose, and androgen levels. METHODS: Twenty-four individuals with DM (12M, 12F) from a tertiary care center were compared with 24 C (12M, 12F). Fasting glucose, insulin, sex hormone binding globulin, androstenedione, dihydroepiandrosterone sulfate, and testosterone were measured. Height, weight, waist/hip measures, and a clinical survey for acanthosis were recorded. A 2-mm skin biopsy from midaxilla of the nondominant arm was taken for pathological review. RESULTS: C and DM were matched for age and body mass index (BMI). Prevalence of microscopic AN in C was 12% (3/24) and in DM was 21% (5/24; NS). In C, AN was predicted by waist, waist/hip ratio, and fasting insulin measures, while none of the variables examined was predicative of AN in DM. CONCLUSIONS: Microscopic acanthosis nigricans was found in similar numbers of people with DM when compared with C. Fasting insulin levels most strongly predicted the presence of AN in C, while no significant predictors of AN were found in the population with DM.

Acanthosis Nigricans↗